NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026

Key Terms

ctdna medical

Circulating tumor DNA (ctDNA) is tiny fragments of genetic material shed by cancer cells into the bloodstream, like breadcrumbs that can reveal a tumor’s presence and genetic makeup without needing a biopsy. For investors, ctDNA matters because tests and technologies that detect and analyze these fragments can speed diagnosis, track treatment response, and signal relapse, creating commercial opportunities in diagnostics, personalized therapies, and monitoring services.

molecular residual disease (mrd) medical

Molecular residual disease (MRD) is the tiny number of cancer cells that remain in a patient after treatment, detected by highly sensitive genetic or molecular tests that can find one cancer cell among thousands or millions of normal cells. MRD matters to investors because it helps predict the chance of relapse and influences whether additional treatment is given; MRD signals are increasingly used as early clinical trial or regulatory endpoints, so positive or negative MRD results can materially affect the market value of diagnostics and therapies—similar to an early warning that shapes future decisions.

phase ii medical

Phase II is the mid-stage clinical trial where a potential drug or medical treatment is tested in a larger group of patients to see if it works and to help determine the best dose and common side effects. For investors, Phase II results matter because they give the first meaningful evidence about effectiveness and safety—like a road test that shows whether a product has real promise before a much bigger, costly final trial and potential regulatory approval.

ffpe medical

FFPE stands for formalin-fixed, paraffin-embedded, a standard laboratory method for preserving tissue samples by chemically fixing them and enclosing them in wax so they keep their structure over time. Think of it like embedding a pressed flower in wax to preserve its shape and details. For investors, FFPE matters because many diagnostic tests, drug development studies and biomarker analyses rely on these preserved samples; their quality and compatibility with laboratory assays affect clinical validation, regulatory approval and the commercial value of pathology and diagnostics products.

antibody-drug conjugate medical

An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.

immunofluorescence medical

A laboratory method that uses specially labeled antibodies that glow under specific light to find and show where particular proteins, cells, or pathogens are located in tissue or fluid samples. Investors care because immunofluorescence is a common diagnostic and research tool used to validate disease markers, confirm how a drug interacts with targets, and support regulatory data—think of it as using glow-in-the-dark paint to prove a product hits the right spot in development.

ihc medical

Immunohistochemistry (IHC) is a laboratory technique that uses labeled antibodies to detect and visually highlight specific proteins inside tissue samples, producing stained patterns pathologists can see under a microscope. For investors, IHC matters because it helps confirm whether a drug or diagnostic hits the intended target in real patient tissues and can support patient selection, clinical trial design and regulatory filings — essentially acting like a map that shows where a therapy is likely to work and reducing clinical and regulatory risk.

tumor microenvironment medical

The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.

The Company will highlight integrated clinical and genomic insights generated through its Oncology Data Solutions platform

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced it will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026 in San Diego, Calif., April 17–22, 2026 (booth #1537).

The abstracts highlight how combining laboratory testing with clinical data can support oncology research, drive AI-based analysis, and help translate findings into clinically relevant insights. By linking testing results with real-world clinical data, NeoGenomics has demonstrated its capabilities to drive deeper characterization of biomarker prevalence, evaluation of testing concordance, and insights that help bridge translational research and clinical application, with the potential to enable cutting-edge oncology therapy development and commercialization.

“Bringing together lab and clinical data is becoming foundational to modern oncology research,” said Tony Zook, CEO at NeoGenomics. “Our collaborations with biopharma partners have allowed us to develop compelling research that we’re proud to present at AACR, showcasing how these insights can directly enhance therapy development and create optionality for providers and patients.”

Presentations at AACR include:

• Oral presentation (Clinical Trials Mini Symposium: Focus on ctDNA): Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): The MERIDIAN Phase II trial
  • Monday, April 20, at 2:30–4:30 PM
• Poster #1106: Rapid identification of comprehensive multi-omic protein and RNA biomarkers on a single FFPE tissue section using a novel integrated nCounter® workflow
  • Sunday, April 19, at 2:00–5:00 PM | Section 43
• Poster #1224: Antibody-Drug Conjugate Immuno-Oncology Panel for Comprehensive Characterization of the Tumor and Associated Microenvironment
  • Sunday, April 19, at 2:00–5:00 PM | Section 47
• Poster #1456: Paletrra™ AI: Automated phenotyping of multiplex immunofluorescence datasets via information maximizing self-training
  • Monday, April 20, at 9:00 AM–12:00 PM | Section 4
• Poster #1993: Real-world landscape of KMT2A and NPM1 variants and fusions in hematologic malignancies
  • Monday, April 20, at 9:00 AM–12:00 PM | Section 23
• Poster #4162: AI-based detection and scoring of TROP2 expression in IHC-stained NSCLC specimens
  • Tuesday, April 21, at 9:00 AM–12:00 PM | Section 3
• Poster #8493: Expression of the ferroptosis suppressor FSP1 but not GPX4 shows significant adverse prognostic effect in diffuse large B-cell lymphoma with wild-type TP53
  • Tuesday, April 21, at 9:00 AM–12:00 PM | Section 20
• Poster #6674: Metabolic reprogramming in advanced renal tumors contributes to a dysfunctional immune response and immune exhaustion within the tumor microenvironment
  • Tuesday, April 21, at 2:00–5:00 PM | Section 48
• Poster #7263: Identification of molecular alterations in soft tissue sarcoma patients with combined pan-cancer CGP and bespoke sarcoma fusion detection testing
  • Wednesday, April 22, at 9:00 AM–12:30 PM | Section 21

Attendees interested in learning more about NeoGenomics’ clinical and genomics insight capabilities can connect with the team onsite at booth #1537.

About NeoGenomics

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding the Company’s research and data capabilities and the potential for those capabilities to drive clinically relevant insights; linking test results to real-world data and its potential to enable cutting-edge oncology therapy development and commercialization; the Company’s collaborations with biopharma partners and the potential clinical relevance of their research findings. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to continue gaining new customers, offer new types of tests, successfully develop and commercialize its linking and data solutions, maintain and expand its biopharma collaborations, and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260413874087/en/

Investor Contact
InvestorRelations@neogenomics.com

Media Contact
Andrea Sampson
asampson@sampsonprgroup.com

Source: NeoGenomics, Inc.